Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...

Two companies have come together to enhance the way imaging technology is used to assess treatment responses in progressive ...

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers ...

Working out with pulmonary fibrosis can be challenging, but columnist Charlene Marshall has found some tips to make exercise easier.

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...

Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team ...

Everyone's IPF journey is unique, columnist Sam Kirton says, but that does not mean our experiences should become a competition.

Garadacimab is under clinical development by CSL and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase II drugs for Idiopathic Pulmonary Fibrosis have a 35% phase ...

Two cases of pulmonary toxicity associated with chronic ingestion of amiodarone are presented. Special emphasis is given to the radiological features which may aid in the clinical diagnosis of ...

Indications for amiodarone treatment were categorized as the primary therapeutic target of SVT, VT, or both SVT and VT. Congestive heart failure was defined as the presence of pulmonary edema, pleural ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is ...